Estimated time to complete activity: 2.0 hours | Release Date: August 10, 2009 | Expiration Date: August 9, 2010
This activity may be accessed at www.educationalconcepts.net.

Clinical trial endpoints that are selected by investigators and the results that are obtained after the conduct of a study are the backbone of evidence-based medicine in any field. A major challenge the oncology community faces is the definition and determination of the meaningful primary and secondary endpoints for clinical trials. Standardization of definitions for efficacy endpoints is needed to increase the consistency of trial conduct and outcome reporting. Inconsistencies confound the analysis, interpretation, and application of trial results by investigators, clinicians, regulatory agencies, sponsors, and patients. There have been recent reports that may make endpoints that have been more secondary in nature, such as disease control rate, quality of life, and functional scanning of tumors, move to the forefront. Recognizing the complexity of today’s treatment decisions, this initiative has been developed to provide a forum for the interactive exchange of ideas and data. Our analysis of the science and evidence-based treatment approaches for the management of lung cancer, specifically the examination of clinical trial endpoints, constitutes a need in the continuing education of oncology healthcare professionals. An educational program that engages learners to identify specific learning needs and integrate new information has been designed to improve patient outcomes.

LEARNING OBJECTIVES

The target audience for this educational initiative is medical oncologists, surgical oncologists, radiation oncologists, pathologists, and all other healthcare professionals managing patients with lung cancer.

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit
Educational Concepts Group, LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Educational Concepts Group, LLC designates this continuing education activity for
2 contact hours (0.2 CEUs). (UPN 199-000-09-032-H01-P).

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period August 10, 2009 through August 9, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test. Participants must view each section in its entirety to receive full credit for this program.

Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit certificates via the website, www.educationalconcepts.net.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Genentech BioOncology and
OSI Oncology.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications,
and warnings.

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

ECG has declared the following financial relationships:
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.  

The following faculty members have declared relevant financial relationships:

Edward S. Kim, MD - Chair
Grants/Research Support
Eli Lilly and Company, Genentech BioOncology, ImClone Systems, sanofi-aventis Group
Consultant Fees
Eli Lilly and Company, Genentech BioOncology, ImClone Systems, sanofi-aventis Group

David Cella, PhD
No relationships to disclose

Richard J. Gralla, MD
Grants/Research Support
sanofi-aventis Group
Consultant Fees
GlaxoSmithKline, Merck & Co., Inc., sanofi-aventis Group
Honorarium
Merck & Co., Inc., sanofi-aventis Group

Karen Kelly, MD
Consultant Fees
Eli Lilly and Company

Fadlo R. Khuri, MD
Grants/Research Support
Novartis
Consultant Fees
ImClone Systems, sanofi-aventis Group, Tragara Pharmaceuticals, Inc.
Speakers' Bureau
sanofi-aventis Group

J. Jack Lee, PhD, DDS
No relationships to disclose

CME/CE INQUIRIES
For further information, please contact: Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325 Atlanta, Georgia 30339
Phone: 1.770.933.1681 Fax: 1.770.933.1692
www.educationalconcepts.net